1. Home
  2. Live Updates
  3. தேசிய கண் நிறுவனம் காட்சி செயல்பாடு

தேசிய கண் நிறுவனம் காட்சி செயல்பாடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தேசிய கண் நிறுவனம் காட்சி செயல்பாடு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தேசிய கண் நிறுவனம் காட்சி செயல்பாடு Today - Breaking & Trending Today

New data shows encouraging results for patients with neuro-degenerative blinding eye disease


New data shows encouraging results for patients with neuro-degenerative blinding eye disease
New data published in the Journal
Science Translational Medicine shows encouraging results in a worldwide clinical trial for patients diagnosed with the neuro-degenerative blinding eye disease; Leber Hereditary Optic Neuropathy (LHON.)
The disease is an inherited form of vision loss estimated to affect 1 in 30,000 to 50,000 individuals. LHON most often afflicts people with rapid onset of blindness in the prime of their life - men and women in their teens or twenties. Males are about four to five times more likely than females to be affected by the condition. ....

Wills Eye Hospital , United States , France General , Haley Hampton , Gensight Biologics , Markl Moster , Robertc Sergott , Juliaa Haller , Emily Henderson , Ophthalmology Service , National Eye Institute Visual Function , Journal Science Translational Medicine , Leber Hereditary Optic Neuropathy , Wills Eye Neuro Ophthalmology Service , Wills Eye , Principal Investigator , Wills Eye Ophthalmologist In Chief , உயில் கண் மருத்துவமனை , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , ஹேலி ஹாம்ப்டன் , எமிலி ஹென்டர்சன் , கண் மருத்துவம் சேவை , தேசிய கண் நிறுவனம் காட்சி செயல்பாடு , இதழ் அறிவியல் மொழிபெயர்ப்பு மருந்து , லேபேர் பரம்பரை பார்வை நரம்பியல் ,

GenSight Biologics Announces Publication of Results from LUMEVOQ REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine


GenSight Biologics Announces Publication of Results from LUMEVOQ REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine
Non-human primate study clarifies mechanism behind contralateral effect
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal
Science Translational Medicine has published results from the REVERSE pivotal Phase III clinical trial of LUMEVOQ
gene therapy in
ND4 Leber Hereditary Optic Neuropathy (LHON) subjects along with key results from a non-human primate study investigating the contralateral effect of the gene therapy. The paper , published in the December issue under the title Bilateral visual improvement with unilateral gene therapy injection for ....

New York , United States , Wills Eye Hospital , France General , United Kingdom , Thomas Jefferson University , City Of , University Hospital , Magali Taiel , Yordak Salermo , Caroline Chevalier , Clinica Neurologica , Barrett Katz , Markl Moster , Laure Blouin , Alfredoa Sadun , Catherine Vignal Clermont , Marion Janic , Istituto Delle Scienze Neurologiche , Guillaume Van Renterghem , Nancyj Newman , Los Angeles , Gensight Biologics , Valerio Carelli , Harvey Masonson , Valerie Biousse ,